Pfizer and BioNTech filed for Covid vaccine authorisation for under-5s?

Question

Accepted Answer

Pfizer and BioNTech Seek US Authorisation for Covid-19 Vaccine in Children Under Five

Pfizer Inc. and its partner BioNTech have submitted a filing to the US drugs regulator, the Food and Drug Administration (FDA), seeking authorisation for their Covid-19 vaccine to be used in children under the age of five. This submission includes data demonstrating that a regimen of three lower-dose shots of the vaccine elicited a robust immune response in children as young as six months old.
Filing Submitted to US FDA

The companies have concluded their filing process with the US Food and Drug Administration. This action signifies their request for regulatory approval to administer their Covid-19 vaccine to the youngest age demographic.
Data Shows Strong Immune Response

The submitted data indicates that the vaccine, administered in three lower-dose shots, has successfully generated a strong immune response. This finding is particularly significant as it has been observed in children from the age of six months upwards.
Focus on Under-Five Age Group

The authorisation being sought specifically targets children under five years of age. This demographic represents a crucial segment for broader vaccination efforts, and the data presented aims to support the safety and efficacy of the vaccine for this group.

Reading history

Hide →

This history is cleared when the page is closed.

Pfizer and BioNTech filed for Covid vaccine authorisation for under-5s?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends